Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: A subgroup analysis in patients already taking or not taking concomitant memantine

Dementia and Geriatric Cognitive Disorders

Volumn 33, Issue 2-3, 2012, Pages 164-173

  Doody, Rachelle S ^a   Geldmacher, David S ^b   Farlow, Martin R ^c   Sun, Yijun ^d   Moline, Margaret ^d   MacKell, Joan ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c INDIANA UNIVERSITY   (United States)

^d EISAI INC   (United States)

^e PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Cognition; Donepezil; Memantine

Indexed keywords

DONEPEZIL; MEMANTINE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APHASIA; ARTICLE; ASTHENIA; BRADYCARDIA; CONFUSION; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; FALLING; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; MULTICENTER STUDY; NAUSEA; NIGHTMARE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INDANS; INTELLIGENCE TESTS; MALE; MEMANTINE; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84860857867     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000338236     Document Type: Article

References (15)

1. Alzheimer's Disease International: World Alzheimer report 2010:the global economic impact of dementia. Alzheimer's Disease International Web site. http://www.alz.co.uk/ research/files/WorldAlzheimerReport2010.pdf.
2. Alzheimer's Association: 2011 Alzheimer's disease facts and figures. Alzheimer's Association Web site. http://www.alz.org/downloads/Facts-Figures- 2011.pdf.
3. Farlow MR, Miller ML, Pejovic V: Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422.
4. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter JM, Minthon L: Donepezil in Alzheimer's disease: What to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-160.
5. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS: Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1.
6. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT: Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38: 1389-1394.
7. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-324.
8. Cummings JL, Schneider E, Tariot PN, Graham SM: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67: 57-63.
9. Feldman HH, Schmitt FA, Olin JT: Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006; 20: 263-268.
10. Schmitt FA, van Dyck CH, Wichems CH, Olin JT: Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis. Alzheimer Dis Assoc Disord 2006; 20: 255-262.
11. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-221.
12. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-607.
13. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A: Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234-1251.
14. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG: The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001; 306: 81-84.
15. Goodin S, Cunningham R: 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-effect profile. Oncologist 2002; 7: 424-436.